| Name | Title | Contact Details |
|---|
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world`s first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis.
Harvard Medtech`s mission is to solve pain and related afflictions by providing unmatched Tele-PainCare™ solutions that promote safe, effective healing holistically and organically in conjunction with, or preferably in lieu of, surgery and prescription pain medications. Our Vx Pain Relief Program uniquely integrates state-of-the-art Virtual Reality Therapy with Behavioral Health Clinicians, who regularly provide psychological and social interventions by telephone to patients in the comfort of their homes while keeping the prescribing physician apprised of the patient`s progress. Our FDA-registered, clinically validated, whole-person approach to delivering safe, effective, at-home care yields more complete, convenient, timely and affordable relief of pain, depression, anxiety and related afflictions while requiring zero investment by the prescribing physician.
Relieve Pain, Restore Hope And Reimagine Your Life. Axon Therapy offers an entirely new way to resolve chronic nerve pain. Let us help you return to the life you’ve been missing, on the other side of pain.
Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius` lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius` Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius` RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. Radius was founded in 2003 and has locations in Waltham and Cambridge, Massachusetts, Parsippany, New Jersey, and Wayne, Pennsylvania.
Medefil Inc is a Glendale Heights, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.